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Abstract Greig cephalopolysyndactyly syndrome (GCPS)
and isolated preaxial polydactyly type IV (PPD-IV) are rare
autosomal dominant disorders, both caused by mutations in
the GLI3 gene. GCPS is mainly characterised by craniofacial
abnormalities (macrocephaly/prominent forehead, hypertelor-
ism) and limbmalformations, such as PPD-IV, syndactyly and
postaxial polydactyly type A or B (PAPA/B). Mutations in the
GLI3 gene can also lead to Pallister–Hall syndrome (PHS) and
isolated PAPA/B. In this study, we investigated 16 unrelated
probands with the clinical diagnosis of GCPS/PPD-IV and
found GLI3 mutations in 12 (75 %) of them (nine familial
and three sporadic cases). We also performed a detailed clin-
ical evaluation of all 12 GLI3-positive families, with a total of
27 patients. The hallmark triad of GCPS (preaxial polydactyly,
macrocephaly/prominent forehead, hypertelorism) was
present in 14 cases (52 %), whereas at least one typical
dysmorphic feature was manifested in 17 patients (63 %).
Upon sequencing of the GLI3 gene, we demonstrated eight
novel and two previously reported heterozygous point muta-
tions. We also performed multiplex ligation-dependent probe
amplification (MLPA) to screen for intragenic copy number
changes and identified heterozygous deletions in the two
remaining cases (16.7 %). Our findings fully support previous
genotype–phenotype correlations, showing that exonic dele-
tions, missense mutations, as well as truncating variants local-
ised out of the middle third of the GLI3 gene result in GCPS/
PPD-IV and not PHS. Additionally, our study shows that
intragenic GLI3 deletions may account for a significant pro-
portion of GCPS/PPD-IV causative mutations. Therefore, we
propose that MLPA or quantitative polymerase chain reaction
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(qPCR) should be implemented into routine molecular diag-
nostic of the GLI3 gene.
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Introduction
Greig cephalopolysyndactyly syndrome (GCPS,
MIM#175700) and isolated preaxial polydactyly type IV
(PPD-IV, MIM#174700) are rare autosomal dominant disor-
ders, both caused by mutations in the GLI3 zinc-finger tran-
scription factor gene (Vortkamp et al. 1991). GCPS is
predominantly characterised by craniofacial abnormalities,
such as macrocephaly, prominent forehead/frontal bossing,
hypertelorism and limb malformation, referred to as PPD-IV,
comprising duplicated halluces, with syndactyly of preaxial
toes, broad or duplicated thumbs, and syndactyly of the third
and fourth fingers. Additionally, postaxial polydactyly type A
or B (PAPA/B) may also occur (Temtamy and McKusick
1978). Isolated PPD-IV is often included into the GCPS
spectrum, as a subtype in which craniofacial dysmorphic
features are mild and indistinguishable from the normal indi-
vidual (Baraitser et al. 1983). Mutations in the GLI3 gene
can also lead to Pallister–Hall syndrome (PHS) and
occasionally to isolated PAPA/B (Kang et al. 1997;
Radhakrishna et al. 1997, 1999). Clinical diagnostic
criteria for GCPS vary among the studies. Biesceker
(2008) proposed a combination of preaxial polydactyly
or abnormally broad hallux or thumb in at least one
limb, accompanied with syndactyly, macrocephaly and
hypertelorism. Since such a full-blown phenotype does
not occur in all patients, more relaxed criteria compris-
ing preaxial polydactyly and at least one feature out of
syndactyly, macrocephaly and hypertelorism were sug-
gested by Johnston et al. (2005). Characteristic features
typical of PHS include the presence of hypothalamic
hamartoma, insertional polydactyly and bifid epiglottis
(Biesecker 2008).
Two syndromic “GLI3 morphopathies”, GCPS and PHS,
are nosologically distinct entities and an efficient algorithm
was developed for the prediction of genotype–phenotype
correlation. First of all, GCPS is caused by a variety of
GLI3 changes, such as chromosomal rearrangements (trans-
locations, large deletions), exon deletions/duplications, and
missense and splicing mutations. Secondly, truncating muta-
tions (frameshift and nonsense) lying between nucleotides
(nt) 1–1,997 and nt 3,482–4,740 of the GLI3 gene result in
GCPS, whereas alterations affecting the middle third (nt
1,998–3,481) cause primarily PHS (Johnston et al. 2005,
2010). There is an important biological basis accounting for
this genotype–phenotype correlation of truncating variants.
For example, mutations located within the amino-terminal
third of the protein, which cut off the zinc-finger DNA
binding domain, lead to a loss of DNA binding capacity.
Additionally, mutations located in the carboxy-terminal
third of the GLI3 protein cause a loss of transactivation
(TA) domain(s) [TA1, amino acids 1,376–1,580; TA2, amino
acids 1,044–1,322, and CBP-binding module, amino acids
827–1,180] and result in the inability of the protein to
activate transcription of the target genes. Conversely, the
truncations in the middle part of the gene are predicted to
generate constitutive repressors that alter the balance be-
tween activator and repressor forms of the GLI3 protein
(Ruppert et al. 1990; Dai et al. 1999; Kalff-Suske et al.
1999).
In this report, we present the clinical and molecular
data of 27 GCPS/PPD-IV Polish patients from 12 fam-
ilies, all carrying GLI3 mutations. We extend the muta-
tional spectrum of the gene, assess if the genotype is
correlated with the phenotype and discuss the functional
consequences of the newly identified GCPS/PPD-IV
causative mutations.
Patients and methods
First, we tested 16 index cases of Polish origin clinically
suspected of PPD-IV and/or GCPS and found GLI3 muta-
tions in 12 of them. Then, from those 12 families for which
GLI3 mutational screening was positive, we recruited 27
patients affected by PPD-IVor GCPS and performed careful
clinical investigation. The local ethics committee approved
the study and a written informed consent was obtained from
all subjects or their legal guardians. Patients were clinically
evaluated and X-ray scans of the affected limbs were taken
in selected cases. Head circumference was measured and
referred to the general population. Macrocephaly was rec-
ognised if the parameter exceeded the 97th percentile.
DNA of all index cases was screened for both point
mutations and intragenic copy number changes involving
the GLI3 gene, by means of sequencing and multiplex
ligation-dependent probe amplification (MLPA). Next, co-
segregation testing was performed in all affected and unaf-
fected family members to check for co-occurrence of the
detected mutation with the phenotype. Alternatively, paren-
tal studies were done in all sporadic cases to confirm a de
novo occurrence of the alterations (parental DNAwas avail-
able for all index patients). The pathogenicity of missense
variants was additionally assessed in silico using PolyPhen2
and SIFT software.
Genomic DNAwas isolated from whole blood according
to the salting-out method. The coding sequence of the GLI3
gene (GenBank accession number NM_000168.5)
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comprised 14 exons, and the flanking intronic regions were
amplified in polymerase chain reaction (PCR) assays and
directly sequenced by means of dye terminator chemistry
(kit v.3, ABI 3130XL). Sequences of the primers used for
amplification and sequencing PCR reactions are given in
Table 1. MLPA for all exons of the GLI3 gene was per-
formed with the use of a commercial kit P179 per the
manufacturer’s protocol (MRC Holland). Data were intra-
normalised by dividing the area of each peak by the overall
area of the reference probes’ peaks in the probemix. Inter-
sample normalisation was obtained by comparing the inves-
tigated samples to several reference control samples
(healthy individuals) run in the same experiment. Relative
peak areas ranging from 0.67 to 1.33 were considered to be
normal, below 0.67 deleted and above 1.33 duplicated
(Schouten et al. 2002).
Results
Clinical presentation
Family A (four affected members) All four patients from
this family presented with bilateral preaxial polysyndactyly
of the feet and broad thumbs (feet polysyndactyly of patient
A-2 is shown in Fig. 1a). Additionally, three patients had
bilateral syndactyly of fingers 3/4 (A-1, A-3 and A-4) and
clinodactyly (A-2, A-3 and A-4), whereas patient A-2 man-
ifested PAPB. Two patients from this family (A-2 and A-3)
had typical craniofacial GCPS features, including macro-
cephaly and prominent forehead with hypertelorism. Only
hypertelorism without macrocephaly/prominent forehead
was noted in patient A-1, whereas none of these traits was
observed in patient A-4.
Family B (two affected members) Both patients from this
family manifested bilateral preaxial polysyndactyly of the
feet. In addition, patient B-2 had bilateral hand syndactyly
of fingers 3/4 and broad thumbs. Hypertelorism was present
in both patients, while only patient B-1 presented with
prominent forehead.
Family C (sporadic case) Patient C-1 presented with bilat-
eral preaxial polysyndactyly of the feet, broad thumbs,
clinodactyly of the fifth fingers, as well as prominent fore-
head and hypertelorism.
Family D (three affected members) All three patients from
this family presented with bilateral preaxial polysyndac-
tyly of the feet, clinodactyly of the fifth fingers, macro-
cephaly, prominent forehead and hypertelorism (for foot
anomaly and facial dysmorphism of patient D-1, see
Fig. 1b, d, respectively). Moreover, patients D-1 and
D-2 manifested bilateral syndactyly of fingers 3/4 and broad
thumbs.
Family E (three affected members) In two patients from this
family (E-1 and E-2), bilateral preaxial polysyndactyly of
the feet and PAPB was noted. Broad thumbs were seen in
patients E-2 and E-3. Craniofacial GCPS features (i.e.
hypertelorism, macrocephaly or prominent forehead) were
not present in any of the family members.
Table 1 Sequences of the pri-
mers used for GLI3 gene ampli-
fication and sequencing
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Family F (sporadic case) Patient F-1 presented with bi-
lateral preaxial polysyndactyly of the feet, syndactyly of
fingers 3/4, as well as craniofacial dysmorphism com-
prising prominent forehead, hypertelorism, bitemporal
narrowing, down-slanted palpebral fissures, epicanthal
folds, broad nasal bridge and low-set ears with promi-
nent pinnae (the facial view of patient F-1 is shown in
Fig. 1c).
Family G (two affected members) Both patients from this
family manifested bilateral preaxial polysyndactyly of the
feet, macrocephaly, prominent forehead and hypertelorism.
Additionally, patient G-1 had bilateral hand syndactyly of
fingers 3/4 and broad thumbs.
Family H (two affected members) Both patients from this
family presented with bilateral preaxial polysyndactyly
of the feet, as well as broad thumbs. Postaxial polydac-
tyly of the feet, hands (type B) and clinodactyly of the
fifth fingers was present only in patient H-1. None of the
patients presented with macrocephaly, prominent forehead or
hypertelorism.
Family I (sporadic case) Patient I-1 manifested right-sided
preaxial foot polysyndactyly, left-sided foot oligodactyly
(missing one toe), bilateral PAPA, as well as large head
circumference, prominent forehead and hypertelorism.
Family J (three affected members) All three patients from
this family presented with bilateral preaxial polysyndactyly
of the feet, broad thumbs and bilateral syndactyly of fingers
3/4 (fingers 3/4/5 in patient J-1). Hypertelorism was diag-
nosed exclusively in patient J-2 and none of the family
members manifested macrocephaly.
Family K (three affected members) Preaxial polysyndactyly
of the feet (bilateral in patients K-1 and K-2, right-sided in
K-3) and broad thumbs were present in all three patients.
Hand syndactyly of digits 3/4 was noted in patient K-2.
Only patient K-1 presented with typical craniofacial GCPS
features (i.e. hypertelorism, macrocephaly and prominent
forehead).
Family L (two affected members) Both patients from this
family exhibited bilateral preaxial polysyndactyly of the
feet, broad and duplicated thumbs, syndactyly of fingers 3/
4, macrocephaly, prominent forehead and hypertelorism.
Molecular findings
Heterozygous GLI3 mutations were found in 12 out 16
probands with the clinical diagnosis of PPD-IV/GCPS. In
three cases, mutation occurred de novo and in nine, it was
inherited from an affected parent. To our knowledge, ten
alterations were novel and included three missense muta-
tions, four frameshifts, one splicing mutation and two ex-
onic deletions, whereas two (both nonsense variants) were
previously reported elsewhere (for a description of the muta-
tions, see Table 2). In all sporadic cases, presence of the
mutation was excluded in both healthy parents, thus,
Fig. 1 Polysyndactyly of the
feet (preaxial polydactyly type
IV, PPD-IV) in patients carrying
a GLI3 causative mutation (a
patient A-2; b patient D-1). Fa-
cial appearance of the presented
GLI3 mutation carriers; c–d
show craniofacial dysmorphism
typical of Greig cephalopoly-
syndactyly syndrome (GCPS)
(c patient F-1; d patient D-1)
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confirming their de novo occurrence in the probands. In
familial cases, the identified alterations fully co-segregated
with the phenotype and were not shown in any of the
unaffected family members. In addition, all three missense
variants were predicted to be probably damaging to the
protein function in the in silico analyses performed by
means of both PolyPhen2 and SIFT software.
In total, we studied 27 patients exhibiting either GCPS or
isolated PPD-IV phenotype, in whom causative GLI3 muta-
tions were detected. Twenty-six patients presented with typi-
cal lower limb malformation (preaxial polydactyly and
syndactyly of preaxial toes, Fig. 1a, b), whereas 25 had at
least one of the following hand affectations (broad thumb,
syndactyly fingers 3/4 or 3/4/5, clinodactyly, PAPA/B). De-
tailed clinical characteristics of the presented cohort is set out
in Table 2, whereas facial dysmorphism seen in some of our
GCPS patients is shown in Fig. 1c, d. The hallmark triad of
GCPS (preaxial polydactyly, macrocephaly and hypertelor-
ism) was present in 14 cases (52 %). At least one typical
craniofacial GCPS feature (macrocephaly/prominent forehead
or hypertelorism) was manifested in 17 patients (63 %). In
total, ten cases presented with no facial dysmorphism, thus,
PPD-IV seemed to be the most appropriate diagnosis.
Discussion
GLI3 mutations are associated with several human syn-
dromic [GCPS, PHS, acrocallosal syndrome] and non-
syndromic (isolated) congenital limb malformations [PPD-
IV, PAPA/B] (Vortkamp et al. 1991; Kang et al. 1997;
Radhakrishna et al. 1997, 1999; Elson et al. 2002). While
clinical criteria for PHS are clear and require the presence of a
hypothalamic hamartoma and insertional polydactyly or iso-
lated hamartoma or polydactyly in a relative of the proband
with PHS (Biesecker 2006, 2008), diagnostic criteria for
GCPS are neither fully defined nor widely accepted. Follow-
ing the strict diagnostic criteria provided by Biesceker (2008),
which included preaxial polydactyly/wide big toes or thumbs
with syndactyly, macrocephaly and hypertelorism, we would
be able to recognise the syndrome in 14 out of 27 mutation
carriers from the presented cohort. If either macrocephaly/
prominent forehead or hypertelorism was considered as a
sufficient craniofacial trait, GCPS could be recognised in only
17 patients. No facial characteristics, a key feature of GCPS,
was observed in ten patients, suggesting that isolated PPD-IV
would be the most appropriate diagnosis in this case.
In 2005, Johnston et al. (2005) proposed relaxed criteria
unhelpful in making the GCPS diagnosis, but useful in
selecting patients for GLI3 molecular analysis. The authors
suggested that patients presenting with preaxial polydactyly
and at least one of the following features, syndactyly, mac-
rocephaly or hypertelorism, would benefit from the GLI3
testing. Of note, out of our 16 unrelated probands analysed
in this study, 12 (i.e. 75 %) showed a positive result of GLI3
screening, thereby, confirming the relatively high efficacy of
the aforementioned criteria in predicting an abnormal mo-
lecular result.
Among all mutations identified in this study, the majority
were truncating variants, including four novel frameshift
mutations, two previously reported nonsense mutations
and two exonic deletions. Frameshifts at codon 166
(p.P166LfsX50; proband F-1) and 454 (p.Q454SfsX48;
family G), as well as a nonsense mutation (p.R366X; family
L) and an out-of-frame exon 4 deletion (family J), introduce
a premature stop codon, which cause the truncation of the
GLI3 protein synthesis within its N-terminal portion. There-
by, the mutant proteins lack all functionally important
domains, including a highly conserved zinc-finger domain
(ZFD), which is crucial for DNA binding capacity in a
sequence-specific manner (Kinzler and Vogelstein 1990).
A similar pathogenic mechanism (i.e. loss of DNA binding
potential) is predicated to take place in case of a splicing
mutation detected in family D, in which we identified A to
G substitution in the AG sequence of the acceptor site at
position −1 of intron 4. This mutation is supposed to result
in exon skipping and premature truncation of the protein
synthesis. The other two detected frameshifts at codon 1,128
(p.D1128AfsX10; family H) and 1,457 (p.A1457AfsX32;
proband I) truncate the GLI3 protein C-terminally to the
DNA binding domain, and localise within the transactiva-
tion domains TA2 and TA1, respectively. The nonsense
mutation p.R792X (family E) terminates the protein down-
stream to both TA domains. Mutations affecting those
regions most probably result in misregulation of the GLI3-
mediated transcriptional activation of the target genes
(Kalff-Suske et al. 1999). Another mutation identified in
family K, a heterozygous intragenic deletion of exons 1–9,
most probably results in a complete loss of one gene copy
(haploinsufficiency). Interestingly, all three missense muta-
tions (p.S1006R, family A; p.S907R, family B; p.D896N,
proband C) mapped within the CBP-binding module. All
three missense variants were predicted to be probably dam-
aging to the protein function in analyses by means of both
PolyPhen2 and SIFT software. An overview of all identified
mutations, along with their intragenic location and putative
pathogenic mechanism, is presented in Table 3 and Fig. 2.
According to the genotype–phenotype correlation,
GCPS, unlike PHS, can be caused by different alterations
of the GLI3 gene, including chromosomal rearrangements
(translocations, large deletions), exon deletions/duplica-
tions, and missense and splicing mutations. Among truncat-
ing mutations (i.e. frameshift and nonsense), those lying in
the N-terminal and C-terminal third of the protein result in
GCPS, whereas alterations affecting the middle third cause
PHS (Johnston et al. 2005, 2010). The type and position of
420 J Appl Genetics (2012) 53:415–422
the novel mutations detected in our patients showed full
correlation between the expected and observed phenotype.
The only exception was a recurrent mutation c.C2374T
(p.R792X) identified in one of our families, localised in
the PHS region. This variant was previously described in
six families presenting with the GCPS phenotype (Kalff-
Suske et al. 1999; Johnston et al. 2005). In our case, a
p.R792X mutation was responsible for isolated PPD-IV,
since none of the three affected members (E-1 to E-3) had
craniofacial involvement. To conclude, our findings fully
Table 3 Location of the mutations within GLI3 domains and putative pathogenic mechanism of each mutation. Pathogenicity of missense variants









Domain Putative pathogenic effect
A GCPS/PPD-IV c.C3018A (p.S1006R) 0 1 CBP/TA Loss of transactivation potential
B GCPS c.C2721G (p.S907R) 0 1 CBP/TA Loss of transactivation potential
C GCPS c.G2686A (p.D896N) 0.01 1 CBP/TA Loss of transactivation potential
D GCPS IVS4-2A>G N/A N/A N/A Loss of the DNA-binding capacity
E PPD-IV c.C2374T (p.R792X) N/A N/A X N-terminal
to TA2, TA1
Loss of transactivation potential
F GCPS c.497delC (p.P166LfsX50) N/A N/A X N-terminal
to ZFD
Loss of the DNA-binding capacity
G GCPS c.1360delC (p.Q454SfsX48) N/A N/A X within ZFD Loss of the DNA-binding capacity
H PPD-IV c.3383delA
(p.D1128AfsX10)
N/A N/A X within TA2 Loss of transactivation potential
I GCPS c.4370insGC
(p.A1457AfsX32)
N/A N/A X within TA1 Loss of transactivation potential
J GCPS/PPD-IV exon 4 deletion
(out-of-frame)
N/A N/A X N-terminal to ZFD Loss of the DNA-binding capacity
K GCPS/PPD-IV exon 1–9 deletion N/A N/A N/A Haploinsufficiency
L GCPS c.C1096T (p.R366X) N/A N/A X N-terminal to ZFD Loss of the DNA-binding capacity
GCPS Greig cephalopolysyndactyly (diagnosed if at least one craniofacial feature out of macrocephaly/prominent forehead and hypertelorism was
present)
PPD-IV preaxial polydactyly type IV (diagnosed if neither macrocephaly/prominent forehead nor hypertelorism was present)
N/A not applicable
GCPS/PPD-IV coincidence of both phenotypes within the same family
CBP/TA CBP-binding domain
X stop codon
TA2, TA1 transactivation domains
ZFD zinc-finger domain
SIFT score: the amino acid substitution is predicted to be damaging if the score is≤0.05 and tolerated if the score is >0.05
PolyPhen2 score: the amino acid substitution is predicted to be damaging if the score is above 0.85
Fig. 2 Schematic view of the GLI3 gene structure and overview of all
exonic point mutations identified in this study. ZFD, zinc-finger do-
main [amino acids (aa) 462–645] reported by Ruppert et al. (1990).
CBP, CBP-binding domain (aa 827–1,132) reported by Dai et al.
(1999). TA2 transactivation domain (aa 1,044–1,322) reported by
Kalff-Suske et al. (1999). TA1 transactivation domain (aa 1,376–
1,580) reported by Kalff-Suske et al. (1999). GCPS, Greig cephalopo-
lysyndactyly syndrome. GCPS is caused by truncating mutations lying
between aa 1–666 and 1,160–1,580 of the protein (Johnston et al.
2005, 2010). PHS, Pallister–Hall syndrome. PHS is caused by muta-
tions affecting the middle third (aa 667–1,160) of the protein (Johnston
et al. 2005, 2010)
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support previous genotype–phenotype correlations corrobo-
rating the usefulness and high predictive value of the algo-
rithm published by Johnston et al. (2005). On the other
hand, one has to emphasise that any genotype–phenotype
correlations based on single mutation carriers or families
are, at best, tentative. Even within the same family, in which
the molecular cause of the disease is identical, there might
be a significant variability of the clinical symptoms between
the affected kindreds (Cohen 2010). Therefore, further stud-
ies are needed in order to prove whether the correlations for
the mutations presented within this report are correct.
In 2 out of our 12 probands (16.7 %), MLPA demonstrated
heterozygous intragenic causative deletions. This type of mu-
tation was recently associated with metopic and/or sagittal
synostosis (Hurst et al. 2011); however, none of our 6 patients
(J-1 to J-3, K-1 to J-3) who carried the deletion had anomalies
of the cranial sutures. Although based on a small sample, our
study shows that intragenic GLI3 deletions may account for a
significant proportion of GCPS/PPD-IV causative mutations.
Therefore, we propose that MLPA or quantitative polymerase
chain reaction (qPCR) should be implemented into routine
molecular diagnostic of the GLI3 gene, especially if the se-
quence analysis detects no pathogenic alteration.
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